Pharmaceutical Business review

Quintiles makes additional investments in China

Shanghai Clinical Research Centre(SCRC), Quintiles’ strategic partner in the China-based lab initiative, will provide lab testing services to customers as part of the agreement.

Quintiles will invest $14m to launch a 4,000-square-meter (43,000 square feet) headquarters in Shanghai.

The Quintiles-SCRC collaboration is the result of last year’s inauguration of Kun Tuo,a local research organisation of Quintiles, which started operating from 1997.

Quintiles operations General Manager Ling Zhen said, "Quintiles recognises the unique needs of our customers in China.By collaborating with SCRC in labs we can help local and international biopharma companies develop new and better medicines to serve China’s enormous unmet medical needs."

SCRC President Rongxing Gan said, "SCRC’s Central Laboratory’s experienced staff and modern technology will be further enhanced through Quintiles’ investments.We are delighted to work closely with Quintiles to further biopharma innovation and improve human health.”